Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma.
A SverrildS CerpsJ J Nieto-FontarigoS RamuM HvidtfeldtMandy MenzelJ KearleyJ M GriffithsJ R ParnesCeleste M PorsbjergLena UllerPublished in: Allergy (2023)
Blocking TSLP with tezepelumab in vivo in asthma reduced the airway epithelial inflammatory response including IL-33 and T2 cytokines to viral challenge without affecting anti-viral host resistance. Our results suggest that blocking TSLP stabilizes the bronchial epithelial immune response to respiratory viruses.